April 8, 2016

San Francisco, CA. June 16 – BioTox Sciences attends the International Society for Stem Cell Research Annual Meeting in San Francisco, California at the Moscone Center West.

Baltimore, MD. November 7-10, 2010 – BioTox Sciences attends the American College of Toxicology's Annual Meeting in Baltimore, Maryland.

Washington, D.C. March 6, 2011 – BioTox Sciences attends the Society of Toxicology: Annual Meeting and Toxicology Expo at the Walter E. Washington Convention Center.

San Diego, CA. April 27-28, 2011 – BioTox Sciences attends the Drug Delivery and Formulation America Summit.

Atlanta, GA. September 28, 2011 -- BioTox Sciences Attends the American Association of Pharmaceutical Scientist Annual Meeting and Exposition in Atlanta, Georgia.

Phoenix, AZ. November 6, 2011 – BioTox Sciences attends the American College of Toxicology's Annual Meeting in Phoenix, Arizona.

CARY, N.C., March 9, 2011 /PRNewswire/ -- iAdvantage Software, Inc., a leading solutions provider for managing development and pre-clinical life science studies, today announced that BioTox Sciences (BTS), a GLP Contract Research Organization, headquartered in San Diego, California, is deploying the eStudy™ hosted solution to manage its GLP and Non-GLP preclinical/nonclinical studies. (Logo: http://photos.prnewswire.com/prnh/20110309/CL62195LOGO ) In 2010, BioTox Sciences expanded its resources from people to facility to accommodate growing Sponsors' needs. The final challenge was selecting a software platform that would handle the different preclinical study types BTS conduct's today, yet flexible enough to meet the ever-changing needs they may...

Company to Focus on Generation of Revenues From Commercialization of Drug Pipeline Based on NexACT(R) Delivery Technology SAN DIEGO, July 6, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has sold its wholly-owned subsidiary, Bio-Quant, Inc. ("Bio-Quant"), a specialty biotechnology Contract Research Organization ("CRO"), to BioTox Sciences ("BioTox"), a San Diego-based CRO. Under terms of the agreement, Apricus Bio will receive a minimum of $5 million in up-front and future earn-out payments, with the potential for as much as $20 million over the next ten years, based on BioTox's currently projected revenues. Additionally, Apricus...